On Thursday, Agilent Technologies got an upgrade to its Relative Strength (RS) Rating, from 70 to 73.
When To Sell Stocks To Lock In Profits And Minimize Losses
IBD's proprietary rating measures market leadership with a 1 (worst) to 99 (best) score. The rating shows how a stock's price performance over the last 52 weeks holds up against all the other stocks in our database.
Over 100 years of market history shows that the market's biggest winners typically have an RS Rating of at least 80 in the early stages of their moves. See if Agilent Technologies can continue to show renewed price strength and hit that benchmark.
Agilent Technologies is now considered extended and out of buy range after clearing a 131.00 buy point in a first-stage cup with handle. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week moving average.
While earnings growth declined in the company's most recent performance report from 7% to 4%, sales grew 10%, up from 6% in the previous report.
Agilent Technologies holds the No. 2 rank among its peers in the Medical-Research Equipment/Services industry group. Medpace Holdings is the No. 1-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
